Announcing the company's new corporate strategy at the 27th AGM here on Tuesday, TPL chairman Sudhir Mehta said that in addition to these steps, the company would, in addition to exports to off-patent countries, also promote exports to select regulated countries. Further, in order to meet the challenges of the international market, TPL had also taken up a major modernisation and expansion project costing Rs 55 crore and was planning to build up regulatory expertise.

On the domestic front, TPL had introduced several new products in the past few months including Nikoran 1V, a first-time cardio offering, and Eurepa, an anti-diabetic medicine. AA series of products are going to be launched in the coming months as well, Mehta said. In addition, TPL has also filed patents for three classes of NCEs both nationally and internationally.

It may be mentioned that the Torrent group has appointed the Boston Consulting Group to chalk out its restructuring and growth strategies. Mehta said the company would continue to focus on the allopathic retail market and enter the higher end of the institutional market. The company plans to intensify the current therapeutic areas, speed up introduction of new molecules and build select molecules as well.

It also plans to acquire brands and companies for better synergy.